Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bangkok Genomics Innovation PCL's Revenue for the
three
months ended in Dec. 2025 was ฿142.3 Mil. Bangkok Genomics Innovation PCL's average Accounts Receivable for the
three
months ended in Dec. 2025 was ฿116.0 Mil.
Hence, Bangkok Genomics Innovation PCL's Receivables Turnover for the
three
months ended in Dec. 2025 was 1.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bangkok Genomics Innovation PCL Receivables Turnover Related Terms
Bangkok Genomics Innovation PCL Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Receivables Turnover of 1.23 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bangkok Genomics Innovation PCL and its competitors. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 64.9%.
Is Bangkok Genomics Innovation PCL's Receivables Turnover too high?
Bangkok Genomics Innovation PCL's current Receivables Turnover is 1.23. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Bangkok Genomics Innovation PCL's value of 1.23 is 77.2% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #131 out of 202 companies for Receivables Turnover. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median Receivables Turnover is 5.39. Bangkok Genomics Innovation PCL's value of 1.23 is 77.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current Receivables Turnover of 1.23 is 77.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current Receivables Turnover is 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Receivables Turnover of 1.23. The current Receivables Turnover is 1.23 and 77.2% below the Medical Diagnostics & Research industry median of 5.39. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Receivables Turnover is 1.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
